SCHEMBL185690

SCHEMBL185690

N#Cc1c(F)cccc1Br

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.43
ALDH1A1 P00352 4/20 0.43
HPGD P15428 2/20 0.43
HSD17B10 Q99714 1/20 0.43
TLR8 Q9NR97 1/20 0.37
TRPV4 Q9HBA0 1/20 0.37
DYRK1A Q13627 1/20 0.36
LMNA P02545 2/20 0.36
NPSR1 Q6W5P4 1/20 0.36
RXFP1 Q9HBX9 1/20 0.36
CUL4A Q13619 1/20 0.35
BCAT1 P54687 1/20 0.35
TAS1R3 Q7RTX0 1/20 0.35
TAS1R1 Q7RTX1 1/20 0.35
TAS1R2 Q8TE23 1/20 0.35
MAPT P10636 3/20 0.34
DRD2 P14416 1/20 0.34
HTR2A P28223 1/20 0.34
HRH1 P35367 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29555331 1.00 KDM4E (0.43) KDM4EALDH1A1HPGDHSD17B10TLR8
SCHEMBL14861620 0.84 KDM4E (0.40) KDM4EALDH1A1HPGDHSD17B10TAS1R3
SCHEMBL1343169 0.83 DYRK1A (0.42) KDM4EALDH1A1HPGDHSD17B10TLR8
SCHEMBL186269 0.83 ALDH1A1 (0.50) KDM4EALDH1A1HPGDHSD17B10TRPV4
SCHEMBL2652911 0.82 ADORA1 (0.39) KDM4EALDH1A1HPGDHSD17B10LMNA
SCHEMBL22904097 0.82 LMNA (0.48) KDM4EALDH1A1HPGDHSD17B10TLR8
SCHEMBL6695099 0.81 ADORA1 (0.38) KDM4EALDH1A1HPGDHSD17B10DYRK1A
SCHEMBL25953713 0.79 TRPV4 (0.38) KDM4EALDH1A1HPGDHSD17B10TRPV4
Cyanide SCHEMBL28871133 0.78 ALDH1A1 (0.47) KDM4EALDH1A1HPGDHSD17B10TRPV4
SCHEMBL18190631 0.77 CA1 (0.39) KDM4EALDH1A1HPGDLMNANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 390 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122011088-A Cyclic peptide compound and preparation method and application thereof 甫康生物科技(上海)股份有限公司 2026-05-12 CN claimed
CN-119528741-A Preparation method of rituximab key intermediate 济南鼎皓医药科技有限公司 2025-02-28 CN claimed
US-20230301186-A1 ORGANIC TRIAZINE CONTAINING MOLECULES FOR USE IN OPTOELECTRONIC DEVICES SAMSUNG DISPLAY CO., LTD. (KR) 2023-09-21 US claimed
EP-4185581-A1 ORGANIC TRIAZINE CONTAINING MOLECULES FOR USE IN OPTOELECTRONIC DEVICES Samsung Display Co., Ltd. (KR) 2023-05-31 EP claimed
CN-116157408-A Triazine-containing organic molecules for optoelectronic devices 三星显示有限公司 2023-05-23 CN claimed
WO-2022018175-A1 ORGANIC TRIAZINE CONTAINING MOLECULES FOR USE IN OPTOELECTRONIC DEVICES CYNORA GMBH (DE) 2022-01-27 WO claimed
CN-122011088-A Cyclic peptide compound and preparation method and application thereof 甫康生物科技(上海)股份有限公司 2026-05-12 CN disclosed
US-20260062393-A1 Compounds CTXT PTY LTD (AU) 2026-03-05 US disclosed
WO-2025229494-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2025-11-06 WO disclosed
EP-3487836-B1 HISTONE ACETYLTRANSFERASE ACTIVATORS AND COMPOSITIONS AND USES THEREOF UNIV COLUMBIA (US) 2025-10-22 EP disclosed
EP-3351533-B1 BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME KAKEN PHARMA CO LTD (JP) 2025-07-23 EP disclosed
US-12365655-B2 Compounds CTXT PTY LTD (AU) 2025-07-22 US disclosed
CN-112334466-B Compounds of formula (I) CTXT私人有限公司 2025-05-30 CN disclosed
EP-1248624-A1 3,4-DIHYDRO-(1H)-QUINAZOLIN-2-ONES AND THEIR USE AS CSBP/p38 KINASE INHIBITORS SmithKline Beecham Corporation (US) 2002-10-16 EP disclosed
WO-2002074772-A1 IMIDAZO-PYRIMIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS MERCK SHARP & DOHME LIMITED (GB) 2002-09-26 WO disclosed
WO-2002074773-A1 IMIDAZO-PYRIMIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS MERCK SHARP & DOHME LIMITED (GB) 2002-09-26 WO disclosed
US-6452056-B1 REDUCING FLUORINATED BENZONITRILE TO A BENZYLAMINE WHICH IS REPLACED WITH A HYDROXYL GROUP ASAHI GLASS COMPANY, LIMITED (JP) 2002-09-17 US disclosed
WO-2002059124-A2 SUBSTITUTED PYRROLOQUINOLINES AND PYRIDOQUINOLINES AS SEROTONIN AGONISTS AND ANTAGONISTS BRISTOL-MYERS SQUIBB COMPANY (US) 2002-08-01 WO disclosed
EP-1114809-A1 PROCESS FOR THE PREPARATION OF FLUOROBENZYL DERIVATIVES Asahi Glass Co., Ltd. (JP) 2001-07-11 EP disclosed
WO-2001037837-A1 3,4-DIHYDRO-(1H)-QUINAZOLIN-2-ONES AND THEIR USE AS CSBP/p38 KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2001-05-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260062393-A1 Compounds SCN2B, ABCB11, SCN1B KDM4E 800/4885ALDH1A1 1864/4885HPGD 4289/4885
US-12365655-B2 Compounds SLC10A1, ABCB11, PCSK9 KDM4E 4009/4885ALDH1A1 982/4885HPGD 752/4885
US-20230301186-A1 ORGANIC TRIAZINE CONTAINING MOLECULES FOR USE IN OPTOELECTRONIC DEVICES OXER1, OXSR1, OR10J3 KDM4E 3458/4885ALDH1A1 1413/4885HPGD 3132/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.